Meibomian Glands and The Diabetic Patient: Is it a Biomarker?
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Key messages
- This small pilot study is the first to document Meibomian Gland loss in DM patients vs HbA1c levels.
- Meibomian Gland loss may be a possible biomarker.
- Infrared imaging in the office and on your iphone may be useful for future evaluation of Meibomian Glands and Diabetes.
Presenting Author
Gloria Wu, MD
University of California
San Francisco School of Medicine, USA
Dr Gloria Wu, graduate of Harvard University, Columbia University, College of Physicians and Surgeons, trained in General Surgery at Mount Sinai Medical Center in New York City, Ophthalmology at New York-Presbyterian / Weill Cornell Medical Center, Retina Vitreous Fellowship at Harvard’s Massachusetts Eye and Ear Infirmary. She is currently clinical adjunct faculty at University of California San Francisco School of Medicine. She has participated as a moderator, reviewer and poster presenter at the Endocrine Society since 2010.
She has had a longstanding interest in mobile health, creating multiple apps since 2014. In 2020, in response to Covid19, she created a free mobile app,Telehealth Eye test. In addition, she founded Eyequix, a mobile app, devoted to eye and vision training for stroke and diabetic patients.
